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Abstract
The recently observed low reproducibility of focus score (FS)
assessment at different section depths in a series of single
minor salivary gland biopsies highlighted the need for a
standardized protocol of extensive histopathological
examination of such biopsies in Sjögren's syndrome. For this
purpose, a cumulative focus score (cFS) was evaluated on three
slides cut at 200-µm intervals from each of a series of 120
salivary biopsies. The cFS was substituted for the baseline FS in
the American–European Consensus Group (AECG) criteria set
for Sjögren's syndrome classification, and then test specificity
and sensitivity were assessed against clinical patient re-
evaluation. Test performances of the AECG classification with
the original FS and the score obtained after multilevel
examination were statistically compared using receiver
operating characteristic (ROC) curve analysis. The diagnostic
performance of AECG classification significantly improved
when the cFS was entered in the AECG classification; the
improvement was mostly due to increased specificity in biopsies
with a baseline FS ≥ 1 but <2. The assessment of a cFS
obtained at three different section levels on minor salivary gland
biopsies can be useful especially in biopsies with baseline FSs
between 1 and 2.
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Introduction
Sjögren's syndrome (SS) is characterized by diffuse
chronic inflammation of exocrine glands, which leads to
symptoms and complaints referred to as 'sicca syndrome'
[1]. No single instrumental or laboratory parameter is avail-
able for the diagnosis of SS, which relies instead on the
evaluation of multiple clinical, serological, functional, and
morphological parameters [2], such as those proposed and
validated by a group of investigators sponsored by the
European Community (now the European Union) [3,4] and
recently revised by the American-European Consensus
Group (AECG) [5]. The presence of chronic inflammatory
infiltrates in lip salivary glands, as assessed with minor sal-
ivary gland biopsy (MSGB), is one of the parameters
included in most criteria sets proposed for SS classifica-
tion [3,5-9]. Salivary gland inflammation is assessed by
scoring the degree of infiltration according to the method
of Greenspan and Daniels, who defined the focus score
(FS) as the number of inflammatory infiltrates of at least 50
cells present in 4 mm2 of gland surface unit [10,11]. Differ-
ent criteria sets consider as positive a FS ≥ 1 or FS ≥ 2
[3,9]. Although the methodology of sampling, processing,
and examining MSGBs has been standardized [10,11], the
reproducibility of the routine histopathological evaluation in
the diagnosis of SS at different section levels within the
same biopsy specimen has been recently challenged
[12,13]. To avoid any bias that might therefore arise, the
examination of multiple levels of tissue has been recom-
mended, to maximize the number of foci, the glandular area,
and the technical quality of the material, although the
AECG = American-European Consensus Group; cFS = cumulative FS; CI = confidence interval; FS = focus score; MSGB = minor salivary gland 
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number of sections required has not yet been standardized
[12].
In this study, we tried to standardize a protocol for his-
topathological MSGB evaluation in which the FS is
assessed by examining a larger area of the biopsy tissue,
and we investigated how the FS obtained affects the
number of patients classified as having SS, as compared
with the routine method, using the classification criteria
recently proposed by the AECG [5]. The diagnostic accu-
racy of the test was validated against the clinical re-evalua-
tion of the patients performed by two experienced
rheumatologists after at least 1 year of follow-up.
Materials and methods
Selection criteria
We retrospectively studied a consecutive series of patients
thoroughly investigated at our hospital between 1998 and
2002 for suspected primary SS, including a follow-up of at
least 1 year after the diagnostic evaluation. Patients with
secondary SS or who had been diagnosed by biopsy as
having nonspecific inflammation, fibrosis, and atrophy of
the gland were excluded [10-12]. Less-than-optimal tissue
area (biopsy section area less than 4 mm2) was not consid-
ered a criterion for exclusion, provided that at least one nor-
motrophic glandular lobule had been sampled.
Baseline clinical and histopathological evaluation
All patients had undergone thorough clinical and instru-
mental evaluation [3,4], including MSGB performed as
suggested by Daniels [11]. The diagnosis of SS was estab-
lished for all patients according to the classification criteria
proposed by the AECG [5]. MSBG samples were fixed in
formalin, processed, and embedded in paraffin according
to standardized laboratory methods. Baseline histopatho-
logical slides containing 4-µm-thick sections stained with
hematoxylin and eosin were reviewed by a pathologist,
blinded to clinical and laboratory data, who recorded for
each patient the number of glands, the sample surface
area, the presence of alterations suggestive of nonspecific
sialoadenitis, and the baseline FS [10,11]. The lymphocytic
focus and the focus score were defined according to
Greenspan and Daniels [10,11]. In individual biopsies, lob-
ules with acinar atrophy and diffuse fibrosis were excluded
from diagnostic evaluation. The histological parameter was
considered as negative in the absence of any inflammatory
infiltrate (FS = 0) and in the presence of less than 1 focus
per 4 mm2 (0 < FS < 1) [5]; the presence of one or more
foci per 4 mm2 was considered positive when the adjacent
glandular parenchyma was histologically normal. We fur-
ther classified patients with a positive FS into two groups,
those with fewer than two foci per 4 mm2 (1 ≤ FS < 2) and
those with two or more (FS ≥ 2). The area of the biopsy sec-
tions was assessed with video-assisted morphometric soft-
ware capable of measuring the area of delineated surfaces
(ImageDB System, Casti Imaging, Cazzago di Pianiga,
Italy). The comparison of automated and manual area meas-
urements of a smaller series of MSGB sections did not
show a significant difference (data not shown). This
prompted us to choose the automated system to simplify
the examination of the large number of samples involved in
the study.
Serial histopathological re-evaluation
Sample blocks were recut at two additional levels, about
200 and 400 µm deeper than the original section. Sections
4 µm thick corresponding to these levels were collected on
separate slides and stained with hematoxylin and eosin.
Considering that an infiltrate of 50 lymphocytes in our sec-
tion had a mean diameter of 50 µm, we assumed that the
interposition of 200 µm between the evaluated sections
was enough to ensure that the FS recorded at each level
was independent of the other two and that if the same
focus was present in two section levels, the focus itself was
large enough to justify repeated scoring. The two new sec-
tions were blindly examined by the same pathologist, who
again recorded the area and the focus score for each level.
For each patient, the total number of foci at all three levels
and the total surface area measured at all levels were used
to calculate a cumulative FS (cFS) for the three sections.
Reclassification of patients
The cFS obtained after re-evaluation was entered in the
AECG criteria set [5], to obtain a re-classification of each
patient. To compare the diagnostic performance of the
original classification and the reclassification, a 'gold stand-
ard' was needed independent of the AECG criteria set. We
adopted as reference standard the opinion of experienced
clinicians, analogously to what had been done by the Euro-
pean Community Study Group on Diagnostic Criteria for
Sjögren's Syndrome when SS and control patients were
selected to validate the proposed criteria [3-5]. Briefly,
three experienced rheumatologists, blinded to the results of
the histopathological re-evaluation, performed a clinical
evaluation of each patient and reviewed the patient's charts
including the original clinical, laboratory, and instrumental
evaluation, and the subsequent documentation covering at
least 1 year of follow-up and treatment response. On this
basis they were requested to judge whether individual
patients had SS.
Statistical analysis
Quantitative data are shown as means ± standard deviation
(SD). Specificity and sensitivity were assessed with their
95% confidence intervals (CI). Differences in frequencies
were evaluated by means of chi-square statistics or the
Fisher exact test, as appropriate. Given the known limita-
tions of diagnostic accuracy as a parameter for measuring
the diagnostic performance of a test, specificity and sensi-
tivity were compared using receiver operatingAvailable online http://arthritis-research.com/content/7/2/R343
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characteristic (ROC) curves [14]. A P value of less than
0.05 was considered to indicate statistical significance. All
tests were two-sided. Analyses were performed with Sta-
tistica for Windows (StatSoft Inc, 2002, Tulsa, OK, USA)
and MedCalc software.
Results
Baseline examination
The study series comprised 138 patients, 65 of whom had
a baseline FS = 0, 14 with 0 < FS < 1, 18 with 1 ≤ FS < 2,
and 41 with FS ≥ 2. Eighteen patients had incomplete clin-
ical data that hampered either the AECG classification or
the clinical re-evaluation. These patients (8 with FS = 0, 3
with 0 < FS < 1, 3 with 1 ≤  FS < 2, and 4 with FS ≥ 2)
were excluded from further analysis. The final series
included 120 patients, for whom demographic, biopsy, and
clinical data and the result of the clinical re-evaluation are
presented in Table 1.
Histological re-evaluation
In 96 (80%) of the 120 biopsies, the FS group did not
change after serial sectioning and calculation of the cFS. In
14 of these biopsies, the FS group changed but this did not
affect that patient's negative or positive status. In the biop-
sies for the other 10 patients, 1 (1.7%) of the 57 with a
baseline FS = 0 and 1 (9%) of the 11 with a baseline score
of 0 < FS < 1 switched to a FS consistent with SS accord-
ing to AECG criteria (FS ≥ 1). At clinical re-evaluation,
these two patients were considered not to have SS. Seven
(46%) of the 15 patients with a baseline score of 1 ≤  FS <
2 and one (3%) of 37 with a baseline FS ≥ 2 switched to a
grade inconsistent with SS (FS < 1). On clinical re-evalua-
tion, 7 of these 8 patients were assessed as not having SS.
Patient reclassification according to AECG criteria
When the cFSs were entered in the AECG criteria set [5],
the baseline classifications of the 63 non-SS patients were
not changed, while the classifications of 7 of the 57
patients originally classified as having SS were changed to
non-SS (Table 2). The classification was changed in 6% of
the 120 patients. Six of these seven patients had a baseline
score of 1 ≤ FS < 2 and one had a baseline FS ≥ 2. On clin-
ical re-evaluation, all these seven patients were judged not
to have SS. The clinical re-evaluation also refuted 7 of the
113 (6.2%) classifications that had not been changed at
biopsy revision. Considering the clinical re-evaluation as
the reference gold standard, the number of false-negative
AECG classifications did not change (3 of 63 AECG non-
SS cases), while the number of false positives was reduced
from 11 to 4 (63.6% reduction).
Table 1
Demographic, biopsy, and clinical data for 120 patients given salivary gland biopsies for Sjögren's syndrome (SS)
Clinical and laboratory parameters FSa = 0 0 < FS < 1 1 ≤ FS < 2 FS ≥ 2
No. of patients 57 11 15 37
Sex 9M/48F 1 M/10 F 0 M/15 F 3 M/34 F
Age (years) 46 ± 12 46 ± 11 54 ± 14 56 ± 13
Baseline biopsy area (mm2) 6.1 ± 5.6 8.3 ± 2.8 8.6 ± 4.3 4.7 ± 2.6
Cumulative area of three biopsies (mm2) 17.1 ± 15.1 21.8 ± 9.3 22.6 ± 12.7 12.9 ± 6.4
Findings [No. (%)]
Dry eyes 49 (86) 9 (81) 14 (93) 33 (89)
Xerostomia 45 (79) 7 (63) 14 (93) 35 (94)
Positive Schirmer's test 24 (42) 4 (36) 9 (60) 18 (51)
Reduced salivary flow rate 30 (53) 7 (63) 13 (86) 34 (91)
Antinuclear antibodies 29 (51) 8 (73) 8 (53) 31 (83)
Ro/SS-A 18 (31) 3 (27) 6 (40) 25 (67)
La/SS-B 3 (5) 0 3 (20) 10 (27)
Rheumatoid factor 27 (47) 5 (45) 7 (46) 33 (89)
SS according to AECG criteria [No. (%)] 7 (12) 1 (9) 15 (100) 34 (92)
SS according to clinical re-evaluation [No. (%)] 7 (12) 0 (0) 8 (53) 34 (92)
aThe focus score (FS) is the number of inflammatory infiltrates of at least 50 cells present in 4 mm2 of salivary gland area. AECG, American-
European Consensus Group; F, female; M, male; SS-A, anti-Ro60 antibodies; SS-B, anti-La antibodies.Arthritis Research & Therapy    Vol 7 No 2    Morbini et al.
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Comparison of sensitivity and specificity between 
baseline and multilevel FS evaluation
In the present series of 120 patients fully evaluated for SS,
the sensitivity and specificity of the baseline AECG criteria
set were 93.9% and 84.5%, respectively. Reclassification
with cFS did not affect sensitivity, whereas specificity
changed to 94.4% (P = 0.056), increasing the accuracy
from 88.3% (95% CI 81.2–93.5) to 94.2% (95% CI 88.3–
97.6). Pairwise comparison of the ROC curves showed a
statistically significant difference between patient classifi-
cation before and after multilevel FS evaluation (difference
between areas: 0.049 [SE 0.021]; 95% CI 0.009–0.089;
P = 0.016) (Fig. 1). Sensitivity and specificity did not
change for biopsies with FS = 0 or FS < 1 (inconsistent
with SS), while specificity increased substantially in biop-
sies consistent with SS (FS ≥ 1) (Table 2). Pairwise com-
parison of the ROC curves showed a statistically significant
difference (P = 0.013) only in biopsies with 1 ≤ FS < 2 (dif-
ference between areas: 0.43 [SE: 0.17]; 95% CI 0.09–
0.76; P = 0.013; Fig. 1). The diagnostic accuracy of the
MSGB histological analysis considered independently of
other criteria changed from 85.8% (95% CI 78.3–91.5) to
90.8% (95% CI 84.2–95.3), but the comparison of the
ROC curves did not show a statistically significant differ-
ence (P = 0.15).
Discussion
In the present study, we show that the histopathological
evaluation of salivary gland biopsies with multilevel section-
ing and assessment of a cumulative focus score (cFS)
changes the baseline classification in 6% of patients eval-
uated for SS and increases the diagnostic performance of
the criteria recently proposed by the AECG for SS classifi-
cation [5]. In particular, multilevel evaluation improved the
diagnostic accuracy of biopsies with a baseline FS
between 1 and 2, which is the most critical cutoff in SS his-
topathological evaluation.
The present study was prompted by a recent paper docu-
menting that MSGB grading of inflammation was scarcely
reproducible at different section depths, and that the differ-
ence between grades recorded at baseline and at deeper
levels was sufficient to change the biopsy from positive to
negative or vice versa in 10% of grade I (FS = 0), 44.4% of
grade II (0 < FS < 1), 88.8% of grade III (1 ≤ FS < 2), and
40% of grade IV (FS ≥ 2) biopsies [13]. The authors of that
paper recommended that multiple sections of MSGB
should be examined to improve the reliability of the his-
topathological grading. However, they did not suggest how
many sections should be examined or how to deal for diag-
nostic purposes with the different scores obtained at differ-
ent levels, nor did they give a clinical interpretation of their
results by entering them in a criteria set for SS patient
classification.
On this basis, we aimed at assessing if the histopathologi-
cal evaluation of a larger area of MSGB tissue, as obtained
by cutting the biopsy sample at additional section levels,
could increase the diagnostic performance of the his-
topathological study and of the AECG criteria set pro-
posed for the classification of SS. We chose a minimum
requirement of three different section levels, by analogy
with the procedure standardized for the histopathological
study of endomyocardial biopsies [15], assuming that a
200-µm distance should ensure the detection of
independent foci on each section while reducing the
chance of missing the smaller ones, thus allowing estima-
tion of the overall density of inflammatory foci with sufficient
precision.
With reference to the diagnostic gold standard, when
patients were classified according to the AECG criteria set
including the cFS, specificity increased by 9.8%, and the
pairwise comparison of the ROC curves showed a statisti-
cally significant improvement of the diagnostic perform-
ance, mostly due to the increased test specificity in
Table 2
Changes in classification determined by multilevel salivary gland biopsies for Sjögren's syndrome (SS)
Test results and diagnostic accuracy FSa = 0 0 < FS < 1 1 ≤ FS < 2 FS ≥ 2T o t a l
No. of patients 57 11 15 37 120
AECG classification changes 0 0 6 (40°%) 1 (3%) 7
Baseline sensitivity (95% CI) 85.7%
(42.2–97.6)
-1 0 0 %
(62.9–100)
94.1%
(80.3–99.1)
93.9%
(83.1–98.6)
Revised sensitivity (95% CI) 85.7%
(42.2–97.6)
-1 0 0 %
(62.9–100)
94.1%
(80.3–99.1)
93.9%
(83.1–98.6)
Baseline specificity (95% CI) 98%
(89.3–99.7)
-0 % b
(0–41.1)
33.3%b
(5.5–88.4)
84.5%
(74.0–92.0)
Revised specificity (95% CI) 98%
(89.3–99.7)
- 85.7%
(42.2–97.6)
66.7%
(11.6–94.5)
94.4%
(86.2–98.4)
aThe focus score (FS) is the number of inflammatory infiltrates of at least 50 cells present in 4 mm2 of salivary gland area. bVery low specificity is 
due to the absence (1 ≤ FS < 2) or extremely low number (FS ≥ 2) of patients classified as non-SS according to AECG criteria. AECG: American-
European Consensus Group; CI: confidence interval; -, could not be evaluated with the available data.Available online http://arthritis-research.com/content/7/2/R343
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biopsies with 1 ≤ FS < 2, whereas the increase was mini-
mal in FS ≥ 2 and null in biopsies inconsistent with SS (0 <
FS < 1). One advantage of the proposed method of MSGB
evaluation is that specificity is increased without affecting
sensitivity; on the other hand, it was shown that improving
sensitivity by means of increasing the cutoff value of posi-
tive FS resulted in a substantial reduction of specificity
[16].
To explain the increased specificity observed with examina-
tion of multilevel salivary gland biopsies, it should be con-
sidered that, because of the uneven distribution of
inflammatory infiltrates in the gland [14], the examination of
a single tissue section might easily either overestimate or
underestimate the FS, while the observation of a larger area
of biopsy sample would allow a more precise quantification
of the focus distribution, provided that the sections are dis-
tant enough to avoid recutting and rescoring of the same
focus. In accordance with this hypothesis, and confirming
previous results [13], after multilevel examination the higher
numbers of FS changes proven to be relevant for classifi-
cation and clinical diagnosis were seen in patients with mild
to moderate MSGB inflammatory infiltrates (1 ≤ FS < 2),
while very few relevant changes were recorded in patients
Figure 1
Statistical comparison of the diagnostic performance of the American-European Consensus Group (AECG) criteria for Sjögren's syndrome with  baseline and cumulative focus scores (FSs) Statistical comparison of the diagnostic performance of the American-European Consensus Group (AECG) criteria for Sjögren's syndrome with 
baseline and cumulative focus scores (FSs). Receiver operating characteristic (ROC) curves were used to compare the sensitivity and specificity of 
the AECG criteria with the baseline focus score and with the FS obtained after multilevel histopathological evaluation, with respect to the gold 
standard of patient re-evaluation by the experienced rheumatologists. The diagnostic performance was significantly improved in the overall series 
(top left panel; P= 0.016), mostly because of the improvement in the group of patients with 1 ≤ FS < 2 (bottom left; P= 0.013). No difference was 
observed when FS = 0. No ROC curve could be obtained in the group of patients with 0 < FS < 1, because of the absence of cases classified as 
Sjögren's syndrome at clinical re-evaluation (positive gold standard). CI, confidence interval.
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with negative or highly positive biopsies (FS < 1 or FS ≥ 2).
We suggest that in mild inflammation, lymphocytic foci are
unevenly distributed through the gland, so that positive
baseline sections can occasionally be followed by sections
with less or no inflammation, whereas negative or highly
positive biopsies (FS < 1 and ≥ 2) are likely to be more
homogeneous. Our observations also confirmed the com-
mon knowledge that no single test can be reliably applied
to the diagnosis of SS [2-9]. In fact, the performance of the
test was significantly improved when the cFS was entered
in the criteria set, but not when the histopathological test
was considered alone.
One potential limit of the present study is represented by
the need to introduce a gold standard reference to assess
the diagnostic accuracy of the test, independent of the
widely accepted AECG criteria set for SS classification. In
fact, after clinical re-evaluation, which we adopted as a gold
standard, some patients appeared to have been misclassi-
fied according to AECG criteria. This only partial corre-
spondence between the judgement of experienced
clinicians and classification criteria is a well-known problem
in the diagnosis of rheumatological disorders and justifies
the requirement of a wide criteria set for patient classifica-
tion. In the absence of single, straightforward diagnostic
parameters, a thorough patient's chart and follow-up revi-
sion by experienced rheumatologists was chosen as refer-
ence gold standard, by analogy with what has been done in
many rheumatological studies, including that of the Euro-
pean Community Study Group on Diagnostic Criteria for
SS [3-5]. Accordingly, a multicenter study would be useful
to better standardize the procedure of evaluating FSs by
oral pathologists, backed by a larger panel of experienced
clinicians, because the clinical performance of SS classifi-
cation criteria could be improved.
Conclusion
The assessment of a cumulative focus score (cFS)
obtained at three different section levels on minor salivary
gland biopsies, cut at least 200 µm apart, can improve the
diagnostic accuracy of the criteria set used for SS classifi-
cation, especially in biopsies with a baseline FS between 1
and 2. Since the value of the MSGB biopsy has been con-
firmed by the recent AECG revision of the SS classification
criteria [5], the increase of the diagnostic performance of
the histological study will further help to correctly identify
SS patients.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
PM participated in the design of the study, performed the
histopathological analysis, coordinated the study, and
drafted the manuscript. AM and RC reviewed and dis-
cussed patients' charts for clinical re-evaluation. OE per-
formed all salivary gland biopsies. CV participated in case
collection and data analysis. CT participated in the design
of the study and performed the statistical analysis. ES and
CM conceived the study and participated in its design. CM
also participated in the clinical re-evaluation of patients. All
authors read and approved the final manuscript.
References
1. Talal N, Moutsopoulos HM, Kassan SS: Sjögrens Syndrome Clin-
ical and Immunological Aspects Heidelberg: Springer Verlag;
1987. 
2. Manthorpe R: Sjögren's syndrome criteria.  Ann Rheum Dis
2002, 61:482-484.
3. Vitali C, Moutsopoulos HM, Bombardieri S: The European Com-
munity Study Group on diagnostic criteria for Sjögren's syn-
drome. Sensitivity and specificity of tests for ocular and oral
involvement in Sjögren's syndrome.  Ann Rheum Dis 1994,
53:637-647.
4. Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron
PY, Kater L, Konttinen YT, Manthorpe R, Meyer O, et al.: Assess-
ment of the European classification criteria for Sjögren's syn-
drome in a series of clinically defined cases: results of a
prospective multicentre study. The European Study Group on
Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis
1996, 55:116-121.
5. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander
EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, et al.:
European Study Group on Classification Criteria for Sjögren's
Syndrome. Classification criteria for Sjögren's syndrome: a
revised version of the European criteria proposed by the
American-European Consensus Group. Ann Rheum Dis 2002,
61:554-558.
6. Manthorpe R, Oxholm P, Prause JU, Schiodt M: The Copenhagen
criteria for Sjögren's syndrome.  Scand J Rheumatol 1986,
Suppl(61):19-21.
7. Skopouli FN, Drosos AA, Papaioannou T, Moutsopoulos HM: Pre-
liminary diagnostic criteria for Sjögren's syndrome. Scand J
Rheumatol 1986, Suppl(61):22-25.
8. Homma M, Tojo T, Akizuki M, Yamagata H: Criteria for Sjögren's
syndrome in Japan. Scand J Rheumatol 1986, Suppl(61):26-27.
9. Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV: Sjögren's syn-
drome. Proposed criteria for classification.  Arthritis Rheum
1986, 29:577-585.
10. Greenspan JS, Daniels TE, Talal N, Sylvester RA: The histopa-
thology of Sjögren's syndrome in labial salivary gland
biopsies. Oral Surg Oral Med Oral Pathol 1974, 37:217-229.
11. Daniels TE: Labial salivary gland biopsy in Sjögren's syndrome.
Assessment as a diagnostic criterion in 362 suspected cases.
Arthritis Rheum 1984, 27:147-156.
12. Vivino FB, Gala I, Hermann GA: Change in final diagnosis on
second evaluation of labial minor salivary gland biopsies. J
Rheumatol 2002, 29:938-944.
13. Al-Hashimi I, Wright JM, Cooley CA, Nunn ME: Reproducibility of
biopsy grade in Sjögren's syndrome. J Oral Pathol Med 2001,
30:408-412.
14. Metz CE: Basic principles of ROC analysis. Semin Nucl Med
1978, 8:283-298.
15. Arbustini E, Gavazzi A, Pucci A, Dealessi F, Angoli L, Mussini A,
Grasso M, Montemartini C, Specchia G, Magrini U: Myocarditis
and cardiomyopathy: diagnosis by endomyocardial biopsy. G
Ital Cardiol 1987, 17:120-126.
16. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Benciv-
elli W, Bernstein RM, Bjerrum KB, Braga S, Coll J, de Vita S, et al.:
Preliminary criteria for the classification of Sjögren's syn-
drome. Results of a prospective concerted action supported
by the European Community.  Arthritis Rheum 1993,
36:340-347.